Close-up TV News - Prolotheray lecture

Reversing Hypertension

Heavy Metals and all diseases

Close-Up TV News - Dr. Calapai's approach

News 12 Interview: Parkinson’s Disease, Glutathione and Chelation Therapy

News 12 Interview: Platelet-rich plasma therapy

Prolotherapy Interview News 12

News 12 Interview: Diabetes and Weight Loss

BACKGROUND: There is no effective treatment for chronic traumatic, ischemic, hypoxic, and anoxic brain injuries. We report the initial success of low pressure (LP) HBOT in their treatment. METHODS: All referrals with chronic stable encephalopathies manifested by perfusion/metabolism deficits on HMPAO SPECT scans that improved on repeat scan immediately after a 1. 5 or 1.75 ATA/90 min HBOT were included. Patients underwent 40(1), 60(1), or 80(16) HBOTs at primarily 1.5 ATA/90 mins q.d. or b.Ld. and standard rehabilitation when possible. Neurologic changes were noted by combinations of history, exam, video, occupational and physical therapists, neuropsychologists, referring doctors, and final SPECT scans. RESULTS: 18 pts (12 traumatic, 2 CVA, 2 anoxia, 1 hypoxia, 1 CP) were evaluated and treated. 18/18 showed motor, behavioral, personality, or cognitive gains. Baseline SPECT was 3.7 yrs (.2-15.2) post injury; rescan post O2 intervention was 22d (1-130) later. Final SPECT scans were performed within 2 weeks of final HBOT. All showed improvement over baseline SPECT. 6/18 patients noted neurological changes on the O2 intervention either in chamber or later that day. 16/18 noted neurological changes by 18 HBOTs (7-33) including emotional lability and personality changes. All noted changes by 40 HBOTs, many had further gains at 60-70, and all were improved at 80 HBOTs. 16/18 patients or their parents requested continuous treatment beyond the study endpoint of 80 HBOTs; 2 (40 and 60 HBOTs) stopped for personal reasons and sinusitis. CONCLUSION: Using SPECT brain imaging and LP HBOT living, non-functioning brain tissue can be identified, assessed for potential recovery (Neubauer-Gottlieb technique), treated, and neurorehabilitation achieved in the above encephalopathies. Clinical changes were reported as early as the first HBOT with neurological thresholds noted at 15-20, 40, and 60-80 HBOTs in many patients. 89% requested further treatment.

* Legal Disclaimer: Chelation and Hyperbaric Therapy, Stem Cell Therapy, and other treatments and modalities mentioned or referred to in this web site are medical techniques that may or may not be considered “mainstream”. As with any medical treatment, results will vary among individuals, and there is no implication or guarantee that you will heal or achieve the same outcome as patients herein.

As with any procedure, there could be pain or other substantial risks involved. These concerns should be discussed with your health care provider prior to any treatment so that you have proper informed consent and understand that there are no guarantees to healing.

THE INFORMATION IN THIS WEBSITE IS OFFERED FOR GENERAL EDUCATIONAL PURPOSES ONLY AND DOES NOT IMPLY OR GIVE MEDICAL ADVICE. No Doctor/Patient relationship shall be deemed to have arisen simply by reading the information contained on these pages, and you should consult with your personal physician/care giver regarding your medical treatment before undergoing any sort of treatment or therapy.

Published on 04-23-2010
Authors: Harch, PG, Gottlieb, SF, Van Meter, KW, Staab, P
Source: Inc. Annual Scientific Meeting held June 22-26, 1994